Mural fails to paint a convincing picture for nemvaleukin
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
MacroGenics cuts down its Tamarack
Vobra-duo is discontinued at long last.
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
SGO 2025 – Genmab’s advantage looks Profound
While Sutro shows why it’s shelved luvelta-T.
Sutro calls time on folate
At long last luvelta-T is shelved, and Sutro seeks a new focus.
